Cancer BiologybioRxivPreprint
Using CCDC6 immunostaining in conjunction with the RAD51 HRD assay as a novel approach to expand PARPi treatment eligibility in HGSOC patients
Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino…·Angela Celetti
The paper investigates CCDC6 mutations in HGSOC and shows their link to HRD and PARPi sensitivity, even in BRCA1/2 wild-type patients.
DOI 10.1101/2025.07.29.667411